Influences of anticoagulant treatment (RIbaroxaban vs warfarin) on Systemic inflammative markers in patients with Heart Failure and atrial fibrillation - Influences of anticoagulant treatment (RIbaroxaban vs warfarin) on Systemic inflammative markers in patients with Heart Failure and atrial fibrillation (IRIS-HF)

ational Cerebral and Cardiovascular Center0 个研究点目标入组 70 人开始时间: 2016年4月1日最近更新: 2023年10月17日

研究概览

暂无简介。

•1) the patients currently receving novel anti-coaglants) 2) the patients with intraventricular thrombus 3) the patients with moderate or severe valvular heart disease 4) the patients requiring mechanical circulatory support 5) the patients waiting for cardiovascular surgery 6) the patients with infective disease or autoimmune disease, or receving steroid 7) the patients with cardiac sarcoidosis 8) the patients who start to receive statin or acetylsaliccylic acid 9) the paients who occurred myocardial infarction or stroke or systemic embolism. 10) the patients who represent creatnine clearance 15ml/min 11) liver cirrhosis, Child B or C 12) intracranial hemorrhage or gastrointenstinal bleeding within 6 months 13) pregnant women 14) the patients receiving cobicistat or HIV protease 15) the patients receiving azole antifungal agents 16) the patiens with warfarin or ribaroxaban sensitivity 17) the patients receiving menatetrenone 18) the patients receiving iguratimod 19) the patiens with advanced cancer 20) the patiens who are participating other prospective clinical trials 21) The physician judge to be unsuitable for the enrollment to this study due to any other reason.

发起方

ational Cerebral and Cardiovascular Center